Page 20 - Greg Laub News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were still anemic despite at least three months of eculizumab therapy. The data were presented at December's In this exclusive MedPage Today video, study co-author Ilene C. Weitz, MD, of Keck School of Medicine at the University of Southern California, discusses the trial's findings. Following is a transcript of her remarks: The PEGASUS study was a study designed to lo...

Following is a transcript of their remarks: Rugo: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me today. N...

Following is a transcript of their remarks: Vinay Prasad, MD: All right, I'm Dr. Vinay Prasad. I'm an associate professor and a practicing hematologist oncologist here at the University of California San Francisco. I'm joined via Zoom by two dear colleagues who are myeloma experts, Aaron Goodman, assistant professor at the University of California San Diego, an expert in bone marrow transplantation and hem malignancies, and Dr. Al-Ola Abdallah at the University of Kansas, also an expert in hematologic malignancies and bone marrow transplant. It's a pleasure to have you both here, sirs. Well, ...

Following is a transcript of their remarks: Susan O'Brien, MD: Hi, everyone, and welcome to this roundtable where we're going to discuss CLL presentations at ASH 2020 this year. I'm Dr. Susan O'Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I'm joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering. An interesting presentation at ASH this year that many people were looking forward to was the trial looking at the combination of what's called U2, which is a novel anti-CD20 a...

Following is a transcript of their remarks: Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me...